Gilead Sciences, Inc. $GILD Stock Holdings Lifted by Ieq Capital LLC

Gilead Sciences logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Ieq Capital increased its Gilead stake by 375.7% in the third quarter, adding 126,764 shares to bring its holdings to 160,503 shares, valued at about $23.9 million.
  • Gilead reported quarterly EPS of $2.55, beating estimates of $2.19, while revenue of $8.30 billion exceeded forecasts and rose 6.8% year over year.
  • The company declared a quarterly dividend of $0.82 per share, equivalent to an annualized yield of about 2%; analysts’ average rating was “Moderate Buy,” with a consensus price target of $171.63.
  • Interested in Gilead Sciences? Here are five stocks we like better.

Ieq Capital LLC lifted its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 375.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 160,503 shares of the biopharmaceutical company's stock after buying an additional 126,764 shares during the period. Ieq Capital LLC's holdings in Gilead Sciences were worth $23,923,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the stock. BlackRock Inc. purchased a new position in Gilead Sciences in the 2nd quarter worth approximately $15,393,785,000. Legal & General Group Plc acquired a new stake in Gilead Sciences in the second quarter valued at approximately $1,316,606,000. Deutsche Bank AG acquired a new stake in Gilead Sciences in the second quarter valued at approximately $918,387,000. Jupiter Topco LLC purchased a new stake in shares of Gilead Sciences during the second quarter valued at approximately $448,021,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of Gilead Sciences during the second quarter valued at approximately $398,905,000. Institutional investors and hedge funds own 83.67% of the company's stock.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $166.53 on Friday. The company has a quick ratio of 1.22, a current ratio of 1.38 and a debt-to-equity ratio of 1.84. Gilead Sciences, Inc. has a fifty-two week low of $116.88 and a fifty-two week high of $176.58. The business has a 50 day moving average price of $156.80 and a two-hundred day moving average price of $142.34. The firm has a market cap of $206.55 billion, a PE ratio of -52.70 and a beta of 0.35.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.19 by $0.36. Gilead Sciences had a negative return on equity of 1.85% and a negative net margin of 12.47%. The company had revenue of $8.30 billion for the quarter, compared to analyst estimates of $7.81 billion. During the same period in the prior year, the company posted $2.47 EPS. Gilead Sciences's quarterly revenue was up 6.8% on a year-over-year basis. Sell-side analysts expect that Gilead Sciences, Inc. will post -0.97 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be given a $0.82 dividend. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.0%. Gilead Sciences's payout ratio is presently -103.80%.

Insider Activity at Gilead Sciences

In other news, EVP Keeley Cain Wettan sold 3,399 shares of the company's stock in a transaction dated Friday, November 6th. The shares were sold at an average price of $164.11, for a total value of $557,809.89. Following the sale, the executive vice president owned 5,360 shares in the company, valued at approximately $879,629.60. This represents a 38.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel O'Day sold 9,810 shares of the company's stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $175.17, for a total transaction of $1,718,417.70. Following the completion of the sale, the chief executive officer owned 551,683 shares in the company, valued at approximately $96,638,311.11. This trade represents a 1.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 237,709 shares of company stock worth $39,799,137 over the last quarter. Company insiders own 0.30% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on GILD. JPMorgan Chase & Co. boosted their target price on shares of Gilead Sciences from $170.00 to $190.00 and gave the stock an "overweight" rating in a research report on Friday, October 30th. TD Cowen set a $175.00 price target on shares of Gilead Sciences in a report on Wednesday. Citigroup raised their price target on shares of Gilead Sciences from $165.00 to $188.00 and gave the company a "buy" rating in a report on Friday, October 30th. Sanford C. Bernstein reaffirmed an "outperform" rating and set a $175.00 price target on shares of Gilead Sciences in a research note on Monday, November 2nd. Finally, Jefferies Financial Group set a $196.00 price objective on shares of Gilead Sciences in a report on Wednesday, November 4th. Twenty-three investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $171.63.

View Our Latest Stock Analysis on Gilead Sciences

Gilead Sciences Profile

(Free Report)

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.

Further Reading

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Gilead Sciences Right Now?

Before you consider Gilead Sciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.

While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines